Soluble Urokinase Receptor as a Promising Marker for Early Prediction of Outcome in COVID-19 Hospitalized Patients

Journal of Clinical Medicine

Biagio Pinchera¹  Ivan Gentile¹  Giuseppe Servillo²  Carmine Iacovazzo²  Maria Vargas²  Gaetano Di Spigna³  Nunzia Montuori³  Margherita Ricciardone³  Loredana Postiglione³  Daniela Spalletti Cernia³  Bianca Covelli³  Filomena Napolitano³ 

[1] Department of Clinical Medicine and Surgery-Section of Infectious Diseases, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy;Department of Neurosciences, Reproductive and Odontostomatological Sciences, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy;Department of Translational Medical Sciences and Center for Basic and Clinical Immunology Research (CISI), University of Naples Federico II, 80131 Naples, Italy;

关键词: biomarkers;    COVID-19;    suPAR;    sepsis;    ARDS;    complement system;   

DOI  :  10.3390/jcm10214914

来源: DOAJ

【 摘 要 】

The Coronavirus disease 2019 (COVID-19), caused by SARS-CoV-2, has rapidly spread to become a global pandemic, putting a strain on health care systems. SARS-CoV-2 infection may be associated with mild symptoms or, in severe cases, lead patients to the intensive care unit (ICU) or death. The critically ill patients suffer from acute respiratory distress syndrome (ARDS), sepsis, thrombotic complications and multiple organ failure. For optimization of hospital resources, several molecular markers and algorithms have been evaluated in order to stratify COVID-19 patients, based on the risk of developing a mild, moderate, or severe disease. Here, we propose the soluble urokinase receptor (suPAR) as a serum biomarker of clinical severity and outcome in patients who are hospitalized with COVID-19. In patients with mild disease course, suPAR levels were increased as compared to healthy controls, but they were dramatically higher in severely ill patients. Since early identification of disease progression may facilitate the individual management of COVID-19 symptomatic patients and the time of admission to the ICU, we suggest paying more clinical attention on patients with high suPAR levels.

【 授权许可】

Unknown